Randall Michael Giuffre - Dec 1, 2022 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Role
Director
Signature
/s/ Amy Culbert, attorney-in-fact
Stock symbol
DMAC
Transactions as of
Dec 1, 2022
Transactions value $
$975
Form type
4
Date filed
12/5/2022, 03:08 PM
Previous filing
Dec 1, 2022
Next filing
Dec 8, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DMAC Voting Common Shares, no par value per share Purchase $975 +819 +0.46% $1.19 178K Dec 1, 2022 Direct F1
holding DMAC Voting Common Shares, no par value per share 25.6K Dec 1, 2022 See footnote F2
holding DMAC Voting Common Shares, no par value per share 21.1K Dec 1, 2022 By Spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 29,829 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 82,937 voting common shares held by Michael Giuffre and his wife jointly and 61,360 voting common shares held by Michael Giuffre individually.
F2 These voting common shares are held by 424822 Albert Ltd, of which Michael Giuffre has sole voting and dispositive power.

Remarks:

This Form 4 report does not include 54,186 shares previously reported as being held by the reporting person's children since the reporting person does not have a pecuniary interest in those shares.